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INTRODUCTION
Prostate cancer is the most common non-
skin cancer in men (1). In the U.S. between
2007 and 2011, the incidence of prostate
cancer was 147.8 per 100,000 men per year,
and its prevalence in 2011 was estimated
to be 2,707,821 (2). Additionally, 43% of
the total U.S. male cancer survivor pop-
ulation are survivors of prostate cancer
(3). Prostate cancer is diagnosed by tis-
sue biopsy, and a patient is most often
referred for a biopsy due to an abnormal
screening serum prostate-specific antigen
level and/or abnormal findings on digi-
tal rectal exam (4). The tumor is char-
acterized based on its stage and grade
(Gleason score). The treatment options
vary based on the severity and risk of the
tumor, as well as the patient’s age and
co-morbid conditions, and include active
surveillance, external beam radiation ther-
apy, brachytherapy, and radical prostatec-
tomy for early stage disease, and androgen
deprivation therapy and chemotherapy for
more advanced disease (5). Due to frequent
early detection of the cancer, the over-
whelming majority of cases (93%) involves
a tumor confined to the prostate or one
that has only spread to regional lymph
nodes, for which the 5-year survival rate
is approximately 100%. Four percent of
cases of prostate cancer involve distant
metastases, for which the 5-year survival
rate is approximately 28% (2). Although
survival rates are excellent for localized
prostate cancer, there are many long-
term effects of treatment that significantly
impact a patient’s daily living, includ-
ing urinary incontinence, sexual dysfunc-
tion, and bowel urgency (6). Additionally,
patients undergoing chemotherapy for
prostate cancer often experience side effects
such as anemia, neutropenia, fatigue, myal-
gia, fever, and diarrhea, among others (7).
DEPRESSION
Depression is known to be associated with
advanced physical illnesses and high symp-
tom burden, including cancer (8). More
specifically, men who have received a diag-
nosis of prostate cancer and have begun
treatment have a significantly increased
incidence of the development of anxiety
and depression compared to their coun-
terparts who do not have prostate cancer
(9, 10). The lifetime prevalence of major
depressive disorder in adults in the U.S. is
17% (11), and research has shown that in
patients with prostate cancer, particularly
those treated with radiotherapy, the preva-
lence of depression is considerably higher
in patients both pre-treatment (27%) and
5 years post-treatment (22%) (12). Addi-
tionally, patients with advanced cancer,
as well as patients who have undergone
chemotherapy, have a higher prevalence
of depression (13, 14). Interestingly, there
is significant variation in the psycholog-
ical effects of prostate cancer depending
on the age of the patient (15). Anxiety
and distress have been found to be less
prevalent in older patients compared to
younger patients, while depression has
been found to be more prevalent in the
former. This indicates that young and old
cancer patients react differently to the
impact of having cancer and undergoing
treatment (15).
SUICIDE RISK
Depression is associated with an increased
risk of suicide (16); about 60% of people
who commit suicide suffer from depression
(17). The increased incidence and preva-
lence of depression in men with prostate
cancer is cause for concern for an increased
risk of suicidal ideation and behavior in
such patients. In fact, in patients diagnosed
with prostate cancer, as well as those who
have been treated and survived the can-
cer, studies have shown an increase in sui-
cidal ideation (18). Additionally, there is
an increased rate of completed suicide in
cancer patients compared to the general
population (19). Prostate, lung, pancre-
atic, and head and neck cancers have been
identified as four specific malignancies that
have higher suicide rates, with rates high-
est among older men (20). Other studies
that have verified a significantly increased
risk of suicide in men with prostate can-
cer indicate an especially increased risk
within 18 months of diagnosis, even in
patients with low-risk cancer, and a more
prolonged risk in patients with metastases.
This is true regardless of marital status,
socioeconomic status, and many other risk
factors (21, 22).
PREVENTION AND MANAGEMENT OF
DEPRESSION AND SUICIDE
We have a number of suggestions regard-
ing these issues. The patients and their
families, as well as medical professionals,
should be educated about the psychiatric
risks associated with prostate cancer so the
patients can be more vigilant in caring for
themselves, as well as realize that what they
may be experiencing is not unusual and
that they can feel comfortable sharing their
experiences with family and professionals
who are equipped to help them. Further-
more, research has shown that educating
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the patient about prostate cancer, such as
in details concerning diagnosis, treatment,
and things he can do to improve his health
(eat healthier, exercise, quit smoking), can
facilitate an improved quality of life for the
patient, including a reduction in depressive
symptoms (23).
Additionally, the risks associated with
the various treatment options should be
made clear when discussing the different
treatment modalities with the patient, for
some are associated with more risks com-
pared to others. For instance, hormone
therapy is associated with prolonged neg-
ative effects on health-related quality of
life and psychological distress compared
to other treatments (24). And research
has shown that patients who have under-
gone a major surgical operation some-
times develop subsyndromal or syndro-
mal post-traumatic stress disorder, which
is associated with depression (25). Also, 2
and 5 years following treatment, patients
who have undergone radical prostatectomy
are more likely to complain of urinary
incontinence and erectile dysfunction, but
less bowel urgency, compared to those
who have undergone radiation therapy. It
should be noted, however, that by 15 years
after treatment those differences in urinary
and sexual outcomes disappear, although
they both continue to experience prob-
lems in these areas (6). Additionally, radio-
therapy has been found to be associated
with a relatively increased risk of depres-
sion compared to other treatments (12).
Thus, these associated risks should func-
tion as part of the equation when deciding
on the most appropriate treatment for a
patient.
It is also important for physicians to
implement techniques of management that
can significantly affect their patients’ mood
and behavior. One of the tools available
is appropriate psychopharmacology that
is focused on the treatment and man-
agement of anxiety and depression. Addi-
tionally, psychotherapy has been shown to
be effective for the treatment of depres-
sion in advanced cancer patients (26).
With regard to prostate cancer, cognitive
behavioral stress-management interven-
tions have been successful in improving
patients’ quality of life. These interventions
include anger management, identifica-
tion of distorted thoughts, assertiveness
training, rational thought replacement,
and utilization of social support (27). Stud-
ies also show that patients who use more
approach coping have better psychological
and physical outcomes compared to those
who use more avoidance coping. Emotion-
focused coping has also been associated
with better sexual function and quality of
life (28).
What has become more obvious is the
need to focus more on those men who
most require help and support. The “broad
brush” approach of offering the same inter-
ventions to well-adjusted, well-educated
men who experience the same quality of
life as the normal population, and to those
experiencing urinary, sexual, or marital dif-
ficulties is unlikely to be effective in terms
of desired outcome and cost. As survival
rates improve, a large number of men will
be living in the aftermath of the disease and
its treatment. The challenge is to develop
and test interventions aimed at helping
these men.
CONCLUSION
Considering how common prostate can-
cer is and the seriousness of its associated
psychiatric risks, further research concern-
ing the prevention and management of
depression and suicidal behavior in men
with prostate cancer should be conducted.
There is a great need to educate the gen-
eral public and medical professionals about
the prevalence and gravity of these issues.
Early and continual screening for symp-
toms of depression and suicidal behavior in
patients with prostate cancer is warranted
due to the significant risk and the available
means to prevent and manage it.
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